Ohio State University Wexner Medical Center (OSWMC) is launching a multi-arm clinical utility and health economics study to measure the accuracy, efficiency and cost-savings impact of using AI tools in diagnosing cancer in a community hospital setting. The research will utilise Paige Prostate Detect, the only FDA-approved AI in pathology for detecting prostate cancer.
Paige Prostate has already been shown to improve the detection of prostate cancer. In this research, community hospital pathologists will be conducting a retrospective real-world data study to analyse differences in the accuracy and read efficiency with which general surgical pathologists detect, grade, and quantify prostate cancers with and without the assistance of the Paige Prostate Suite, compared to a subspecialist reference diagnosis.
The study will also examine differences in time and resource utilisation based on the use of AI. Qualitatively, this will help determine the impact of the Paige Prostate AI applications on community pathologists, factoring in subspecialist skill access, patient treatment and management pathways, and the level of confidence in diagnosis with and without Paige’s AI applications.
“The American Cancer Society estimates there will be more than 288,000 new cases of prostate cancer in the United States in 2023 alone, and more than 10% of them will be fatal,” said Dr David Klimstra, Co-Founder and Chief Medical Officer at Paige. “The study by OSWMC and its affiliates, using Paige, will provide greater insight into the impact AI has on their diagnostic capabilities, and ultimately help pathologists and oncologists feel confident in the accuracy and efficiency of AI to support them in detecting, diagnosing and treating prostate cancer patients.”
OSWMC has curated the study cohort and aim to initiate study reads later this month. “AI-powered diagnostic solutions such as Paige are on their way to revolutionising pathology practice,” said Dr Swati Satturwar, Clinical Assistant Professor of Pathology and the study’s Principal Investigator. “This retrospective study in collaboration with Paige will showcase the effectiveness of AI in the community setting and will provide real-life evidence to enhance adoption of AI for routine clinical use.”
